|
|
||||||||
1 Department of Radiology, Thomas Jefferson University Hospital, 132 S. 10th
St., 1096 Main Bldg., Philadelphia, PA 19107.
2 Present address: Department of Diagnostic Radiology, Chonnam National
University Medical School, 8 Hackdong, Dongku, Kwangju, South Korea.
3 Present address: Department of Radiology, Hokkaido University School of
Medicine, North-15, West-7, Kita-Ku, 0608638, Sapporo, Japan.
OBJECTIVE. To determine the significance in patients with cirrhosis of small (<20 mm) hepatic nodules that show no hyperintensity on T2-weighted MR images but that enhance during arterial phase MR imaging, we reviewed the cases of patients with such nodules.
MATERIALS AND METHODS. Our review of radiology reports yielded 68 nodules in 40 patients with cirrhosis that showed no hyperintensity on T2-weighted MR images but had rapid enhancement during arterial phase MR imaging after administration of a gadolinium contrast agent. Thirty-four patients (60 nodules) had multiple follow-up MR imaging examinations (range of length of follow-up, 1-72 months; average length of follow-up, 15 months 2 weeks). The final diagnosis of the nodule was determined by pathology reports or after at least 2 years of follow-up to ensure nodule stability and, therefore, benignity. Two radiologists independently reviewed MR images of the nodules, noting the size, signal intensity on T1- or T2-weighted images, and homogeneity of contrast enhancement.
RESULTS. Nine (13%) of the 68 nodules were hepatocellular carcinomas (HCCs). The size of nodules on the first MR examination was between 4 and 20 mm (mean size, 9.5 mm). No significant correlation between the diagnosis of HCC and nodule signal intensity (p = 0.48) or contrast enhancement homogeneity (p = 0.56) on first MR examination was found. Positive predictive value (PPV) and negative predictive value (NPV) for diagnosing HCC on the basis of nodule growth were 100% and 98%, respectively. For diagnosing HCC on the basis of a change in nodule signal intensity, the PPV was 60% and the NPV was 91%. For diagnosing HCC on the basis of a change of enhancement homogeneity, the PPV was 63%, and the NPV was 94%.
CONCLUSION. A finding of growth in small, early-enhancing nodules in patients with cirrhosis is highly predictive of HCC. When small nodules are observed on a single examination, close follow-up of the patient appears appropriate.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Y K KIM, C S KIM, and Y M HAN Detection of small hepatocellular carcinoma: comparison of conventional gadolinium-enhanced MRI with gadolinium-enhanced MRI after the administration of ferucarbotran Br. J. Radiol., June 1, 2009; 82(978): 468 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Marin, M. Di Martino, A. Guerrisi, G. De Filippis, M. Rossi, S. Ginanni Corradini, R. Masciangelo, C. Catalano, and R. Passariello Hepatocellular Carcinoma in Patients with Cirrhosis: Qualitative Comparison of Gadobenate Dimeglumine-enhanced MR Imaging and Multiphasic 64-Section CT Radiology, April 1, 2009; 251(1): 85 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Willatt, H. K. Hussain, S. Adusumilli, and J. A. Marrero MR Imaging of Hepatocellular Carcinoma in the Cirrhotic Liver: Challenges and Controversies Radiology, May 1, 2008; 247(2): 311 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Choi, D. G. Mitchell, S. K. Verma, D. Bergin, V. J. Navarro, A. B. Malliah, C. McGowan, H.-W. L. Hann, and S. K. Herrine Hepatocellular Carcinoma with Indeterminate or False-Negative Findings at Initial MR Imaging: Effect on Eligibility for Curative Treatment Initial Observations Radiology, September 1, 2007; 244(3): 776 - 783. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Holland, E. M. Hecht, W. Y. Hahn, D. C. Kim, J. S. Babb, V. S. Lee, A. B. West, and G. A. Krinsky Importance of Small (<=20-mm) Enhancing Lesions Seen Only during the Hepatic Arterial Phase at MR Imaging of the Cirrhotic Liver: Evaluation and Comparison with Whole Explanted Liver Radiology, December 1, 2005; 237(3): 938 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kanematsu, S. Goshima, H. K. Hussain, T. D. Johnson, H. V. Nghiem, and I. R. Francis Does T2-weighted MR Imaging Really Add No Value in Detection and Characterization of Focal Lesions in Cirrhotic Liver? * Dr Hussain and colleagues respond: Radiology, February 1, 2005; 234(2): 638 - 640. [Full Text] |
||||
![]() |
J A Guthrie Cirrhosis and focal liver lesions: MRI findings Imaging, September 1, 2004; 16(4): 351 - 363. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. McKenzie, D. Lim, B. J. Ransil, M. Morrin, I. Pedrosa, E. N. Yeh, D. K. Sodickson, and N. M. Rofsky Shortening MR Image Acquisition Time for Volumetric Interpolated Breath-hold Examination with a Recently Developed Parallel Imaging Reconstruction Technique: Clinical Feasibility Radiology, February 1, 2004; 230(2): 589 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bhartia, J. Ward, J. A. Guthrie, and P. J. Robinson Hepatocellular Carcinoma in Cirrhotic Livers: Double-Contrast Thin-Section MR Imaging with Pathologic Correlation of Explanted Tissue Am. J. Roentgenol., March 1, 2003; 180(3): 577 - 584. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Heiken Invited Commentary RadioGraphics, September 1, 2002; 22(5): 1037 - 1039. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |